New EU Approvals
Executive Summary
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, including Novartis's Adakveo for preventing recurrent vaso-occlusive crises in patients with sickle cell disease. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization announcement and product type (eg, medicine, vaccine, biologic).
You may also be interested in...
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
EU Review Gets Under Way For Curative Vision Loss Gene Therapy
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: